News

With targeted treatment using both medical therapy for transthyretin-associated cardiac amyloidosis (ATTR-CA) and valve replacement for aortic stenosis (AS),…

AbstractEpidermolysis bullosa (EB) is a rare, heterogeneous, hereditary, chronic skin disorder with severe cutaneous and extracutaneous involvement. With the…

 FRANKFORD (WPVI) -- Heart failure often follows heart attacks, diabetes, or high blood pressure. However, a very different cause is being identified more and…

– Selected to Attend In-Person Event on June 5 led by FDA Commissioner Marty A. Makary, M.D., M.P.H. –LOS ANGELES, CA, June 06, 2025 (GLOBE NEWSWIRE) -- Immix…

Immix Biopharma and its subsidiary Nexcella are currently conducting a phase 1b/2 clinical trial (NCT06097832; NEXICART-2) in the United States aimed at evaluating…

 “So far, the data is quite promising to share that this is very safe... I'm hoping that by the next 6 months, we will have much more mature data, more…

Light chain (AL) amyloidosis is a rare but serious blood disease that develops when aberrant immune plasma cells produce abnormal “light chain” proteins. These…

The BCMA-directed CAR T-cell therapy NXC-201 led to fast-onset responses that proved durable and were characterized by low-grade cytokine release syndrome (CRS) and…

Topline results were announced from a phase 3 trial evaluating birtamimab in patients with amyloid light chain (AL) amyloidosis.Birtamimab is an investigational…

Immunoglobulin light chain (LC) amyloidosis (AL) is one of the most common types of systemic amyloidosis but there is no reliable in vivo model for better…